Last reviewed · How we verify
PF-07976016 (pf-07976016)
PF-07976016 is a novel therapeutic agent under development by Pfizer. Without specific FDA mechanism text provided, a complete summary cannot be generated at this time. Please provide the FDA mechanism of action and approved indication for accurate clinical characterization.
At a glance
| Generic name | pf-07976016 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Taken once daily |
| Therapeutic area | Metabolic |
| Phase | discontinued |
Approved indications
Pipeline indications
- Obesity — discontinued
Common side effects
Key clinical trials
- A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity (PHASE2)
- A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults (PHASE1)
- A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men (PHASE1)
- Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity (PHASE1)
- A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07976016 CI brief — competitive landscape report
- PF-07976016 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI